Antileukemic activity of lysophosphatidic acid acyltransferase-beta inhibitor CT32228 in chronic myelogenous leukemia sensitive and resistant to imatinib.

@article{Rose2006AntileukemicAO,
  title={Antileukemic activity of lysophosphatidic acid acyltransferase-beta inhibitor CT32228 in chronic myelogenous leukemia sensitive and resistant to imatinib.},
  author={Paul La Ros{\'e}e and Taiping Jia and Shadmer Demehri and Nicolai Haertel and Peter de Vries and Lynn Bonham and David Hollenback and Jack W. Singer and Junia V. Melo and Brian J. Druker and Michael Werner Nikolaus Deininger},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2006},
  volume={12 21},
  pages={6540-6}
}
PURPOSE Lysophosphatidic acid acyltransferase (LPAAT)-beta catalyzes the conversion of lysophosphatidic acid to phosphatidic acid, an essential component of several signaling pathways, including the Ras/mitogen-activated protein kinase pathway. Inhibition of LPAAT-beta induces growth arrest and apoptosis in cancer cell lines, implicating LPAAT-beta as a potential drug target in neoplasia. EXPERIMENTAL DESIGN In this study, we investigated the effects of CT32228, a specific LPAAT-beta… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 34 references

p 14 ARF induces G 2 cell cycle arrest in p 53 - and p 21 - deficient cells by down - regulating p 34 cdc 2 kinase activity

NormandG, PG Hemmati, B Verdoodt
JBiol Chem • 2005

In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib - resistant Bcr - Abl - positive cell lines

K Johnson, AS Corbin
Blood • 2004

Antitumor activity of lysophosphatidic acid acyltransferase - h inhibitors , a novel class of agents , inmultiplemyeloma

HideshimaT, HayashiT Chauhan D
Cancer Res • 2003

Similar Papers

Loading similar papers…